Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?

作者: Focke Ziemssen , Bianka Sobolewska

DOI: 10.2165/11594720-000000000-00000

关键词:

摘要: CATT (Comparison of Age-related macular degeneration [AMD] Treatment Trials) examined the efficacy ranibizumab and bevacizumab for treatment neovascular AMD. This prospective, randomized, but unblinded trial revealed a significant improvement in vision with both treatments terms visual acuity; importantly, patients juxtafoveal choroidal neovascularization (CNV) retinal pigment epithelial detachments were not excluded from study. Monthly drugs resulted similar increases acuity, although angiograms indicated that was superior reducing fluid leakage. As study also differentiated between fixed regimen an as-needed (pro re nata [PRN]) dosing regimen, larger sample size Bonferroni statistical correction necessary. The equivalence PRN to monthly could be confirmed. Almost all frequent deviations protocol (referring retreatment criteria: 25.7-28.5%) under-treatment. Since this applied equally, under-treatment alone explain loss acuity observed arm. generally associated lesion after 12 months compared regimens. investigators accepted drawbacks incomplete masking allow co-payment by Medicare. assessments drug trials are often politically motivated, higher demands non-inferiority superiority design must emphasized. A comparison per-protocol last-observation-carried-forward analysis has yet been published; ongoing subgroup might highlight impact different characteristics. While provided further evidence treatment, differences adverse events two (e.g. rate serious ranibizumab) reported; however, these still have analysed, sizes previous studies needing taken into account. Preclinical imply some their event profiles. possible increased risk ruled out clinical case series because follow-up intervals adequate. large discrepancy price versus US means cost-benefit is warranted. lack quality-of-life data prevented calculation appropriate context its performance ophthalmological setting. Thus, suggests favourable achieved very administration Although there certain safety caveats, focus on analyses obtaining longer expected yield additional information relevance.

参考文章(62)
Derjung M Tarn, Debora A Paterniti, John Heritage, Ron D Hays, Richard L Kravitz, Neil S Wenger, Physician communication about the cost and acquisition of newly prescribed medications. The American Journal of Managed Care. ,vol. 12, pp. 657- 664 ,(2006)
Focke Ziemssen, Salvatore Grisanti, Karl Ulrich Bartz-Schmidt, Martin S. Spitzer, Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs & Aging. ,vol. 26, pp. 295- 320 ,(2009) , 10.2165/00002512-200926040-00002
F. Ziemssen, K. U. Bartz-Schmidt, S. Grisanti, (Neben-) Wirkungen der VEGF-Inhibition Der Ophthalmologe. ,vol. 103, pp. 484- 492 ,(2006) , 10.1007/S00347-006-1354-3
Focke Ziemssen, Peter Heiduschka, Ulrich Schraermeyer, Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina-the Journal of Retinal and Vitreous Diseases. ,vol. 27, pp. 1154- ,(2007) , 10.1097/IAE.0B013E3180CA7DAF
Sandra Cassard, Emily W. Gower, Rohit Varma, Ronald Klein, Laura Chu, Adverse Event Rates Following Intravitreal Injection of Avastin or Lucentis for Treating Age-Related Macular Degeneration Investigative Ophthalmology & Visual Science. ,vol. 52, pp. 6644- 6644 ,(2011)
Daniel F Martin, Maureen G Maguire, GSet al Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe, None, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. ,vol. 364, pp. 1897- 1908 ,(2011) , 10.1056/NEJMOA1102673
Derjung M. Tarn, Debora A. Paterniti, Bradley R. Williams, Camille S. Cipri, Neil S. Wenger, Which Providers Should Communicate Which Critical Information About a New Medication? Patient, Pharmacist, and Physician Perspectives Journal of the American Geriatrics Society. ,vol. 57, pp. 462- 469 ,(2009) , 10.1111/J.1532-5415.2008.02133.X
Jignesh J. Patel, Margaret A.S. Mendes, Mark Bounthavong, Melissa L.D. Christopher, Daniel Boggie, Anthony P. Morreale, Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. Journal of Evaluation in Clinical Practice. ,vol. 18, pp. 247- 255 ,(2012) , 10.1111/J.1365-2753.2010.01546.X
Larry E. Miller, Morgan E. Stewart, The blind leading the blind: use and misuse of blinding in randomized controlled trials. Contemporary Clinical Trials. ,vol. 32, pp. 240- 243 ,(2011) , 10.1016/J.CCT.2010.11.004
Giuseppe Querques, Raimondo Forte, Elya Berboucha, Domenico Martinelli, Gabriel Coscas, Gisele Soubrane, Eric H. Souied, Spectral-Domain versus Time Domain Optical Coherence Tomography before and after Ranibizumab for Age-Related Macular Degeneration Ophthalmic Research. ,vol. 46, pp. 152- 159 ,(2011) , 10.1159/000325027